Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
LIWANLI Innovation Co., Ltd. (3054.TW)
New Taipei City, TW
LIWANLI Innovation Co., Ltd. operates within the biomedical science sector, concentrating on the development and distribution of nutrition and healthcare solutions. The company's diverse product portfolio, which notably features the Vigoway line and various powdered formulations, is designed to serve a wide range of consumers, including men, women, seniors, and children. Its extensive offerings encompass products such as probiotic enzymes, active nutrients, resveratrol red grape extract, and a variety of soft gels (including those with algae DHA, shea butter with type II collagen, and algae astaxanthin Q10). Other specialized items include cordyceps militaris powder, tooth guard tablets, bovine and goat's milk bites, bilberry tablets, and DHA and vitamin D3 drops, among others. The firm was formerly known as Carry Technology International Co., Ltd. before officially adopting its current name, LIWANLI Innovation Co., Ltd., in 2015. Established in 1980, the company's headquarters are located in New Taipei City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.93% | -6.65% | -11.17% | +116.75% | +169.39% | +103.39% | +173.86% | +245.55% | +195.96% | +178.75% | -70.53% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+26.6% ★ Q1'26: +643.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+590.0% ★ Q1'26: +7,100.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-77.2% Q1'26: +8.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-56.4% Q1'26: +53.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-11.6% Q1'26: +31.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +23.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.05× Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Li-Ching Chen | President & Chairman | — | male |
| Teng-Yin Chang | Finance Officer & Accounting Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3054.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
